Research Projects

This database contains information on EU funded dementia research projects, undertaken since 2007. It is the product of a mapping exercise of European funding programmes for dementia research conducted by Alzheimer Europe in 2020. This database is not an exhaustive resource of information. It contains information about dementia research projects that are funded by European programmes including FP7, H2020, IMI, JPND, AAL and the third EU Health programme. The mapping exercise and database were expanded in 2025, to include projects funded under Horizon Europe (including IHI). For these projects, the database reports the maximum contribution from the European Commission rather than the total project budget, so funding figures may not be directly comparable across all entries.
For an overview of projects, Alzheimer Europe is involved in, visit: https://www.alzheimer-europe.org/our-work/current-work

Filters

(Clear all)

Transferring autonomous and non autonomous cell degeneration 3D models between EU and USA for development of effective therapies for neurodegenerative diseases (ND)

CROSS-NEUROD

Neurodegenerative diseases (NDs), such as Dementia, Parkinson’s and motor neuron diseases, are a major and continuously growing worldwide health issue, particularly devastating for patients and their families. Yet, no cures are available, largely due to the lack of knowledge of ND pathogenic mechanisms. Strikingly, co-occurrence of several NDs in...

Funding Programme
Start Date
End Date
Total Funding
€ 693 000
European Countries Involved

Transgenic dissection of the neural circuitry of memory and dementia

MECEDGE

Our memories are arguably what make us who we are, making dementia a particularly cruel disease. Decades of research have revealed that two interconnected brain regions, the medial entorhinal cortex (MEC) and hippocampus (HP), are required for successful spatial memory formation in mammals. Each region contains specialized neurons that fire...

Funding Programme
Start Date
End Date
Total Funding
€ 196 400
European Countries Involved

Translational implications of the discovery of brain-draining lymphatics

BrainDrain

In 2010, 800 billion Euros was spent on brain diseases in Europe and the cost is expected to increase due to the aging population. – Here I propose to exploit our new discovery for research to alleviate this disease burden. In work selected by Nature Medicine among the top 10 ”Notable Advances” and by Science as one of the 10 ”Breakthroughs of the...

Funding Programme
Start Date
End Date
Total Funding
€ 2 420 429
European Countries Involved

TS4NC: Therapeutic S4N Chelation targeting Alzheimer's Disease.

TS4NC

Despite enormous research efforts across academia and pharmaceutical industry, all clinical trials over the last decade have failed in finding a treatment for Alzheimer’s Disease (AD) which remains one of the greatest challenges in drug discovery. Taking consideration all together three prevailing AD hypotheses: Amyloid Cascade, Metal Ions and...

Funding Programme
Start Date
End Date
Total Funding
€ 212 934
European Countries Involved

Ultrafast photonics for the detection and recognition of toxic spine-structures of amyloid aggregates linked to neurodegenerative disease

UPRECON

Projections indicate that, by 2050, every person aged 85 years or more will be diagnosed with a cognition-related disease. While there is currently no clear strategy for curing such diseases, there are promising developments in the early diagnosis of disease and the inhibition of worsening symptoms. Building on results obtained during my post...

Funding Programme
Start Date
End Date
Total Funding
€ 134 462
European Countries Involved

Unbalanced Wnt signalling in AD: a DNA methylation effect

eWAD

Growing evidence suggests that unbalanced Wnt signalling contributes to early stages of Alzheimer´s Disease (AD). mRNA levels of the Wnt antagonist Dikkoff1 (Dkk1) are increased in AD brains and by Amyloid-ß (Aß) in vitro. Importantly, suppression of Dkk1 activity protects synapses from Aß. Genome-Wide Association Studies also provide evidence for...

Funding Programme
Start Date
End Date
Total Funding
€ 183 455
European Countries Involved

Uncover mechanisms of unconventional secretion of tau using functional CRISPR screens - From basic discoveries to neurodegenerative disease therapeutics

SeCRT

Most of secreted proteins transit through the endoplasmic reticulum (ER) and the Golgi apparatus. However, eukaryotic cells secrete cytosolic proteins, which do not enter the ER. Proteins that use this “unconventional secretory pathway” include factors with critical functions and deregulation of their transport is associated to a wide range of...

Funding Programme
Start Date
End Date
Total Funding
€ 224 934
European Countries Involved

Understanding selective neuronal vulnerability in Alzheimer’s disease

NEVULA

The aim of this action is to understand the mechanisms behind the susceptibility of enthorinal cortex II (ECII) neurons to neurofibrillary tangle (NFT) formation in Alzheimer´s disease. To do so we will modulate the expression of the genes that according to NetWAS (Network-wide Association Study) are more directly involved in NFT formation in ECII...

Funding Programme
Start Date
End Date
Total Funding
€ 247 059
European Countries Involved

Unmasking cellular and molecular networks encoding risk and resilience in Alzheimer’s disease

AD_AGING_AND_GENDER

Alzheimer’s disease (AD) is a crucial problem in our society, raising the need for new therapeutic targets. Evidence suggests multiple non-neuronal cells are implicated in the systemic deficits of AD, but the complex cellular diversity in the brain hampers the investigation of specific cells and their interactions. Moreover, the course of the...

Funding Programme
Start Date
End Date
Total Funding
€ 1 500 000
European Countries Involved

Unraveling the Molecular Changes that Drive the Repression of the Unfolded Protein Response with Ageing

UCUPA

What defines the functional specialization of a cell is its unique proteome. Proteins need to be translated and properly folded to ensure their biological function. Several protein quality control pathways have arisen during evolution, some of them specialized in monitoring protein folding in specific organelles . As a result of ageing, animals...

Funding Programme
Start Date
End Date
Total Funding
€ 212 934
European Countries Involved

UpSurgeOn Academy: A multilevel educational platform for neurosurgical training.

UpSurgeOn Academy

UpSurgeOn is an Italian SME established in 2017, by Neurosurgeons for Neurosurgeons, with a focus on creating a educational platform composed by different educational apps, training and simulation devices actually in the Neurosurgical arena. We have 15 employees, including a combination of neurosurgeons, software developers, technicians and...

Funding Programme
Start Date
End Date
Total Funding
€ 71 429
European Countries Involved

Validation of a fast and simple peripheral blood diagnostic biomarker kit for Alzheimer’s disease

ADDIA

The French SME Amoneta Diagnostics has previously developed a diagnostic kit for Alzheimer’s disease (AD) based on two blood biomarkers that are scientifically proven to be associated with AD. The company holds the intellectual property for specific fluorescent probes that can detect these biomarkers in small amounts of blood using flow cytometry....

Funding Programme
Start Date
End Date
Total Funding
€ 4 998 625
European Countries Involved
 
Acknowledgement
Alzheimer Europe's database on research projects was developed as part of the 2020 Work Plan which received funding under an operating grant from the European Union’s Health Programme (2014–2020).